Mutant p53 facilitates pro-angiogenic, hyperproliferative phenotype in response to chronic relative hypoxia

Cancer Letters

Volumn 249, Issue 2, 2007, Pages 209-219

  Kamat, Chandrashekhar D ^a   Green, Dixy E ^a   Warnke, Linda ^a   Thorpe, Jessica E ^a   Ceriello, Antonio ^b   Ihnat, Michael A ^a  

^a UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF WARWICK   (United Kingdom)

Author keywords

Angiogenesis; Apoptosis; Chronic hypoxia; HIF 1 ; p53; p53 mutant; Vascular endothelial growth factor

Indexed keywords

HYPOXIA INDUCIBLE FACTOR 1; HYPOXIA INDUCIBLE FACTOR 1ALPHA; MUTANT PROTEIN; PROTEIN MDM2; PROTEIN P53; VASCULOTROPIN;

ANGIOGENESIS; APOPTOSIS; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; HUMAN; HUMAN CELL; HYPOXIA; PHENOTYPE; PRIORITY JOURNAL; PROTEIN SECRETION; SIGNAL TRANSDUCTION; TRANSACTIVATION; WILD TYPE;

ANOXIA; APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; MUTATION; NEOVASCULARIZATION, PATHOLOGIC; OXYGEN; PHENOTYPE; PROTO-ONCOGENE PROTEINS C-MDM2; TUMOR SUPPRESSOR PROTEIN P53; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 33947358207     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2006.08.017     Document Type: Article

References (57)

1. Zhu H., and Bunn H.F. Signal transduction. How do cells sense oxygen?. Science. 292 (2001) 449-451
2. Maxwell P.H., and Ratcliffe P.J. Oxygen sensors and angiogenesis. Semin. Cell Dev. Biol. 13 (2002) 29-37
3. Harris A.L. Hypoxia-a key regulatory factor in tumour growth. Nat. Rev. Cancer 2 (2002) 38-47
4. Brown J.M. Tumor microenvironment and the response to anticancer therapy. Cancer Biol. Ther. 1 (2002) 453-458
5. Goda N., Ryan H.E., Khadivi B., McNulty W., Rickert R.C., and Johnson R.S. Hypoxia-inducible factor 1alpha Is essential for cell cycle arrest during Hypoxia. Mol. Cell Biol. 23 (2003) 359-369
6. Sutherland R.M., Sordat B., Bamat J., Gabbert H., Bourrat B., and Mueller-Klieser W. Oxygenation and differentiation in multicellular spheroids of human colon carcinoma. Cancer Res. 46 (1986) 5320-5329
7. Choi K.S., Bae M.K., Jeong J.W., Moon H.E., and Kim K.W. Hypoxia-induced angiogenesis during carcinogenesis. J. Biochem. Mol. Biol. 36 (2003) 120-127
8. Riva C., Chauvin C., Pison C., and Leverve X. Cellular physiology and molecular events in hypoxia-induced apoptosis. Anticancer Res. 18 (1998) 4729-4736
9. Wang G.L., Jiang B.H., Rue E.A., and Semenza G.L. Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension. Proc. Natl. Acad. Sci. USA 92 (1995) 5510-5514
10. Wang G.L., and Semenza G.L. Characterization of hypoxia-inducible factor 1 and regulation of DNA binding activity by hypoxia. J. Biol. Chem. 268 (1993) 21513-21518
11. Takahashi T., Sugishita Y., Nojiri T., Shimizu T., Yao A., Kinugawa K., Harada K., and Nagai R. Cloning of hypoxia-inducible factor 1alpha cDNA from chick embryonic ventricular myocytes. Biochem. Biophys. Res. Commun. 281 (2001) 1057-1062
12. Yu F., White S.B., Zhao Q., and Lee F.S. HIF-1alpha binding to VHL is regulated by stimulus-sensitive proline hydroxylation. Proc. Natl. Acad. Sci. USA 98 (2001) 9630-9635
13. Maxwell P.H., Wiesener M.S., Chang G.W., Clifford S.C., Vaux E.C., Cockman M.E., Wykoff C.C., Pugh C.W., Maher E.R., and Ratcliffe P.J. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature. 399 (1999) 271-275
14. Ravi R., Mookerjee B., Bhujwalla Z.M., Sutter C.H., Artemov D., Zeng Q., Dillehay L.E., Madan A., Semenza G.L., and Bedi A. Regulation of tumor angiogenesis by p53-induced degradation of hypoxia-inducible factor 1alpha. Genes Dev. 14 (2000) 34-44
15. Semenza G.L. Angiogenesis in ischemic and neoplastic disorders. Annu. Rev. Med. 54 (2003) 17-28
16. Bergers G., and Benjamin L.E. Tumorigenesis and the angiogenic switch. Nat. Rev. Cancer 3 (2003) 401-410
17. Gomez-Lazaro M., Fernandez-Gomez F.J., and Jordan J. p53: twenty five years understanding the mechanism of genome protection. J. Physiol. Biochem. 60 (2004) 287-307
18. Blagosklonny M.V., An W.G., Romanova L.Y., Trepel J., Fojo T., and Neckers L. p53 inhibits hypoxia-inducible factor-stimulated transcription. J. Biol. Chem. 273 (1998) 11995-11998
19. Graeber T.G., Osmanian C., Jacks T., Housman D.E., Koch C.J., Lowe S.W., and Giaccia A.J. Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumors. Nature. 379 (1996) 88-91
20. Yu J.L., Rak J.W., Coomber B.L., Hicklin D.J., and Kerbel R.S. Effect of p53 status on tumor response to antiangiogenic therapy. Science 295 (2002) 1526-1528
21. Feki A., and Irminger-Finger I. Mutational spectrum of p53 mutations in primary breast and ovarian tumors. Crit. Rev. Oncol. Hematol. 52 (2004) 103-116
22. An W.G., Kanekal M., Simon M.C., Maltepe E., Blagosklonny M.V., and Neckers L.M. Stabilization of wild-type p53 by hypoxia-inducible factor 1alpha. Nature 392 (1998) 405-408
23. Blagosklonny M.V., Giannakakou P., Romanova L.Y., Ryan K.M., Vousden K.H., and Fojo T. Inhibition of HIF-1- and wild-type p53-stimulated transcription by codon Arg175 p53 mutants with selective loss of functions. Carcinogenesis. 22 (2001) 861-867
24. Kieser A., Weich H.A., Brandner G., Marme D., and Kolch W. Mutant p53 potentiates protein kinase C induction of vascular endothelial growth factor expression. Oncogene 9 (1994) 963-969
25. Mukhopadhyay D., and Datta K. Multiple regulatory pathways of vascular permeability factor/vascular endothelial growth factor (VPF/VEGF) expression in tumors. Semin. Cancer Biol. 14 (2004) 123-130
26. Kamat C.D., Green D.E., Curilla S., Warnke L., Hamilton J.W., Sturup S., Clark C., and Ihnat M.A. Role of HIF signaling on tumorigenesis in response to chronic low-dose arsenic administration. Toxicol. Sci. 86 (2005) 248-257
27. Marks M.G., Shi J., Fry M.O., Xiao Z., Trzyna M., Pokala V., Ihnat M.A., and Li P.K. Effects of putative hydroxylated thalidomide metabolites on blood vessel density in the chorioallantoic membrane (CAM) assay and on tumor and endothelial cell proliferation. Biol. Pharm. Bull. 25 (2002) 597-604
28. Hachiya M., Chumakov A., Miller C.W., Akashi M., Said J., and Koeffler H.P. Mutant p53 proteins behave in a dominant, negative fashion in vivo. Anticancer Res. 14 (1994) 1853-1859
29. Kamech N., and Seif R. Effect of microtubule disorganizing or overstabilizing drugs on the proliferation of rat 3T3 cells and their virally induced transformed derivatives. Cancer Res. 48 (1988) 4892-4896
30. Araya R., Uehara T., and Nomura Y. Hypoxia induces apoptosis in human neuroblastoma SK-N-MC cells by caspase activation accompanying cytochrome c release from mitochondria. FEBS Lett. 439 (1998) 168-172
31. Camenisch G., Stroka D.M., Gassmann M., and Wenger R.H. Attenuation of HIF-1 DNA-binding activity limits hypoxia-inducible endothelin-1 expression. Pflugers Arch. 443 (2001) 240-249
32. Famulski W., Sulkowska M., Wincewicz A., Kedra B., Pawlak K., Zalewski B., Sulkowski S., Koda M., and Baltaziak M. P53 correlates positively with VEGF in preoperative sera of colorectal cancer patients. Neoplasma. 53 (2006) 43-48
33. Liu J., Shibata T., Qu R., Ogura M., and Hiraoka M. Influences of the p53 status on hypoxia-induced gene expression. J. Radiat. Res. (Tokyo) 45 (2004) 333-339
34. Zhang H., Zhang Z., Xu Y., Xing L., Liu J., Li J., and Tan Q. The expression of hypoxia inducible factor 1-alpha in lung cancer and its correlation with P53 and VEGF. J. Huazhong Univ. Sci. Technol. Med. Sci. 24 (2004) 124-127
35. Thomlinson R.H., and Gray L.H. The histological structure of some human lung cancers and the possible implications for radiotherapy. Br. J. Cancer 9 (1955) 539-549
36. Wu J., Parungo C., Wu G., Kang P.M., Laham R.J., Sellke F.W., Simons M., and Li J. PR39 inhibits apoptosis in hypoxic endothelial cells: role of inhibitor apoptosis protein-2. Circulation 109 (2004) 1660-1667
37. Dong Z., Venkatachalam M.A., Wang J., Patel Y., Saikumar P., Semenza G.L., Force T., and Nishiyama J. Up-regulation of apoptosis inhibitory protein IAP-2 by hypoxia. Hif-1-independent mechanisms. J. Biol. Chem. 276 (2001) 18702-18709
38. Bruick R.K. Expression of the gene encoding the proapoptotic Nip3 protein is induced by hypoxia. Proc. Natl. Acad. Sci. USA 97 (2000) 9082-9087
39. Carmeliet P., et al. Role of HIF-1alpha in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis. Nature 394 (1998) 485-490
40. Mazars R., Spinardi L., BenCheikh M., Simony-Lafontaine J., Jeanteur P., and Theillet C. p53 mutations occur in aggressive breast cancer. Cancer Res. 52 (1992) 3918-3923
41. Visakorpi T., Kallioniemi O.P., Heikkinen A., Koivula T., and Isola J. Small subgroup of aggressive, highly proliferative prostatic carcinomas defined by p53 accumulation. J. Natl. Cancer Inst. 84 (1992) 883-887
42. Mayer A., Wree A., Hockel M., Leo C., Pilch H., and Vaupel P. Lack of correlation between expression of HIF-1alpha protein and oxygenation status in identical tissue areas of squamous cell carcinomas of the uterine cervix. Cancer Res. 64 (2004) 5876-5881
43. Cayre A., Rossignol F., Clottes E., and Penault-Llorca F. aHIF but not HIF-1alpha transcript is a poor prognostic marker in human breast cancer. Breast Cancer Res. 5 (2003) R223-R230
44. Lee C.H., Lee M.K., Kang C.D., Kim Y.D., Park do Y., Kim J.Y., Sol M.Y., and Suh K.S. Differential expression of hypoxia inducible factor-1 alpha and tumor cell proliferation between squamous cell carcinomas and adenocarcinomas among operable non-small cell lung carcinomas. J. Korean Med. Sci. 18 (2003) 196-203
45. Aebersold D.M., Burri P., Beer K.T., Laissue J., Djonov V., Greiner R.H., and Semenza G.L. Expression of hypoxia-inducible factor-1alpha: a novel predictive and prognostic parameter in the radiotherapy of oropharyngeal cancer. Cancer Res. 61 (2001) 2911-2916
46. Birner P., Schindl M., Obermair A., Plank C., Breitenecker G., and Oberhuber G. Overexpression of hypoxia-inducible factor 1alpha is a marker for an unfavorable prognosis in early-stage invasive cervical cancer. Cancer Res. 60 (2000) 4693-4696
47. Shibaji T., Nagao M., Ikeda N., Kanehiro H., Hisanaga M., Ko S., Fukumoto A., and Nakajima Y. Prognostic significance of HIF-1 alpha overexpression in human pancreatic cancer. Anticancer Res. 23 (2003) 4721-4727
48. Hegde P.U., et al. Tumor angiogenesis and p53 mutations: prognosis in head and neck cancer. Arch. Otolaryngol. Head Neck Surg. 124 (1998) 80-85
49. Zietz C., Rossle M., Haas C., Sendelhofert A., Hirschmann A., Sturzl M., and Lohrs U. MDM-2 oncoprotein overexpression, p53 gene mutation, and VEGF up-regulation in angiosarcomas. Am. J. Pathol. 153 (1998) 1425-1433
50. Vermeulen P.B., Roland L., Mertens V., Van Marck E., De Bruijn E.A., Van Oosterom A.T., and Dirix L.Y. Correlation of intratumoral microvessel density and p53 protein overexpression in human colorectal adenocarcinoma. Microvasc Res. 51 (1996) 164-174
51. Fan S., El-Deiry W.S., Bae I., Freeman J., Jondle D., Bhatia K., Fornace Jr. A.J., Magrath I., Kohn K.W., and O'Connor P.M. p53 gene mutations are associated with decreased sensitivity of human lymphoma cells to DNA damaging agents. Cancer Res. 54 (1994) 5824-5830
52. Hawkins D.S., Demers G.W., and Galloway D.A. Inactivation of p53 enhances sensitivity to multiple chemotherapeutic agents. Cancer Res. Cancer Res. 54 (1994) 5824-5830
53. Wattel E., Preudhomme C., Hecquet B., Vanrumbeke M., Quesnel B., Dervite I., Morel P., and Fenaux P. p53 mutations are associated with resistance to chemotherapy and short survival in hematologic malignancies. Blood. 84 (1994) 3148-3157
54. Lowe S.W., Bodis S., McClatchey A., Remington L., Ruley H.E., Fisher D.E., Housman D.E., and Jacks T. p53 status and the efficacy of cancer therapy in vivo. Science. 266 (1994) 807-810
55. Aas T., Borresen A.L., Geisler S., Smith-Sorensen B., Johnsen H., Varhaug J.E., Akslen L.A., and Lonning P.E. Specific P53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients. Nat. Med. 2 (1996) 811-814
56. Jung M., Notario V., and Dritschilo A. Mutations in the p53 gene in radiation-sensitive and -resistant human squamous carcinoma cells. Cancer Res. 52 (1992) 6390-6393
57. Schmid T., Zhou J., Kohl R., and Brune B. p300 relieves p53-evoked transcriptional repression of HIF-1. Biochem. J. Pt. (2004)